An experimental gene therapy treatment did not cause a patient's linkurl:death; earlier this year, according to a federal advisory committee. The National Institutes of Health's Recombinant DNA Advisory Committee announced the findings this morning (Dec. 3) and made recommendations to alter the design of the study, which was cleared by the US Food and Drug Administration to linkurl:resume; last week. Building upon preliminary findings, which __The Scientist__ linkurl:reported; in September, the RAC presented additional data fingering a systemic linkurl:fungal infection; and massive retroperitoneal hemorrhage as the primary causes of 36-year-old Jolee Mohr's death in July. RAC chairman Howard Federoff suggested that the trial should boost hematological monitoring of patients and said that the treatment should not be administered to patients who show physiological signs of infection prior to treatment, or those who have histories of opportunistic infection. Federoff also said that informed consent forms in this study should be revised...

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?